Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Shares of Coherus BioSciences rose 4.5% to $1.8 in pre-market activity after it released positive med-stage results for its ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

This significant downturn reflects a staggering 1-year change, with the company's stock value eroding by -84.83%. Investors have watched with concern as Omega, known for its innovative approaches in ...

1The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 2Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

One of the best ways to address the gap between healthcare providers and patients is by making diagnostic processes more ...

OPRA] is setting up hygge desks in the most beautiful cabins across Norway and is looking for ten people to browse the web from them for a ...